常染色体显性多囊肾病患者的衰弱风险:一项匹配队列研究
本研究基于台湾大学医院整合医学数据库(2006-2021)开展回顾性队列研究,纳入775例ADPKD患者与3100例倾向评分匹配的单纯性肾囊肿对照。中位随访4.8年,ADPKD与衰弱发生(HR 1.20,95%CI 0.69-2.08)或衰弱恶化(HR 0.98,95%CI 0.82-1.17)均无显著关联,亚组及竞争风险分析结果一致。
要点
- ADPKD患者衰弱发生与恶化风险较匹配的单纯性肾囊肿对照无显著升高。
- 年龄、肾功能及基线衰弱状态亚组中,ADPKD与衰弱关联均不显著。
- ADPKD可能不独立于肾功能影响功能衰退,但研究人群事件数有限。
核心结论
- 在匹配队列中,ADPKD与衰弱发生或恶化的风险增加无显著关联。
- ADPKD可能不独立于其对肾功能的影响而驱动功能衰退。
研究设计与样本
- 回顾性队列研究,使用台湾大学医院整合医学数据库(2006-2021)。
- 纳入775例ADPKD患者和3100例经1:4倾向评分匹配的单纯性肾囊肿对照。
- 衰弱状态采用FRAIL量表评估,随访4.8年。
主要发现
- 随访期间88例(2.3%)发生衰弱,810例(20.9%)衰弱恶化。
- ADPKD与衰弱发生的风险比HR 1.20(95%CI 0.69-2.08)。
- ADPKD与衰弱恶化的风险比HR 0.98(95%CI 0.82-1.17)。
- 按年龄、肾功能和基线衰弱分层的亚组结果一致,竞争风险分析后仍一致。
关键数值与推荐
- 衰弱评估采用FRAIL量表。
- 倾向评分匹配比例为1:4。
临床怎么用
- ADPKD患者衰弱风险未见独立升高,临床可更多关注肾功能等通用危险因素。
- 对ADPKD患者仍需常规评估衰弱,但无需因ADPKD本身过度归因。
局限性
- 回顾性队列设计可能存在残余混杂。
- 衰弱发生事件数较少(88例),统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Autosomal dominant polycystic kidney disease (ADPKD) is a major inherited cause of end-stage kidney disease (ESKD), associated with various systemic complications. Frailty, a degenerative condition linked to adverse health outcomes, may be influenced by ADPKD and its complications; however, data on this association is limited. This study investigated whether ADPKD is associated with increased risk of incident or worsening frailty. METHODS: We conducted a retrospective cohort study, using the National Taiwan University Hospital Integrate Medical Database (2006-2021). Adults with ADPKD or simple kidney cysts (SKCs) were identified. After applying exclusion criteria and 1:4 propensity score (PS) matching, 775 patients with ADPKD and 3100 matched SKC controls were included. Frailty status was assessed using the FRAIL scale. Kaplan-Meier curves and Cox proportional hazards were used to evaluate associations with incident and worsening frailty, adjusting for clinical variables. Competing risk analysis accounting for mortality or ESKD was performed. RESULTS: Over 4.8 years of follow-up, 88 participants (2.3%) developed incident frailty and 810 (20.9%) experienced worsening frailty. ADPKD was not significantly associated with higher risk of incident frailty (hazard ratio [HR]: 1.20, 95% confidence interval [CI]: 0.69-2.08) or worsening frailty (HR: 0.98, 95% CI: 0.82-1.17). Results remained consistent across subgroups stratified by age, kidney function, and baseline frailty, and after accounting for competing mortality or ESKD. CONCLUSION: In this matched cohort study, ADPKD was not associated with an increased risk of incident or worsening frailty. These findings suggest that ADPKD may not independently drive functional decline beyond its impact on kidney function.
引用
- Wang J, Lee SY, Chao CT, et al. Frailty Among Patients With ADPKD. Kidney Int Rep. 2025. PMID: 41278355. doi:10.1016/j.ekir.2025.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。